F-1/A: Regentis Biomaterials Eyes NYSE American Listing with $11 Million IPO

Regentis Biomaterials is seeking to raise capital through an initial public offering to advance its GelrinC cartilage repair technology.

Summary

• Regentis Biomaterials is filing an amendment to its F-1 registration statement for a proposed IPO.
• The company aims to list its Ordinary Shares on the NYSE American under the symbol RGNT.
• The IPO involves offering 1,000,000 Ordinary Shares with an anticipated price between $10.00 and $12.00 per share.
• The company expects to receive approximately $9.1 million in net proceeds, or $10.6 million if the over-allotment option is exercised in full.
• Proceeds will be used for development activities, operations, research and development, EU marketing development, repayment of loans, and a payment to the Chairman of the board.
• GelrinC, the company's lead product, is a cell-free hydrogel implant for knee cartilage repair, already CE marked in Europe.
• A pivotal trial is underway in the US and Europe to support a PMA submission to the FDA.
• The company is an emerging growth company and a foreign private issuer, which allows for reduced reporting requirements.
• The company has a limited operating history and has incurred significant operating losses since its inception, and anticipates that it will incur continued losses for the foreseeable future.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company highlights the potential of its GelrinC technology and its progress towards FDA approval, it also acknowledges significant financial challenges and risks associated with its business.

Positives

• GelrinC has already received CE mark approval in Europe.
• The FDA has granted an IDE for the pivotal trial, permitting PMA submission with two-year follow-up data of 80 patients and with 40 additional patients to be treated thereafter.
• The company is an emerging growth company and a foreign private issuer, which allows for reduced reporting requirements.

Negatives

• The company has a limited operating history and has incurred significant operating losses since its inception, and anticipates that it will incur continued losses for the foreseeable future.
• The company has not generated any revenue from product sales and may never be profitable.
• Even if this offering is successful, the company will need to raise substantial additional funding, which may not be available on acceptable terms, or at all.
• The company's financial statements contain an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern, which could prevent it from obtaining new financing on reasonable terms or at all.

Risks

• The company may not succeed in advancing the development of its product, achieve manufacturing stability and capacity, demonstrate sufficient clinical evidence or commercialize its product and generate significant revenues.
• Clinical failure can occur at any stage of clinical development.
• The company operates in a very competitive business environment.
• The company expects to derive most of its revenues from the sales of GelrinC.
• The company is dependent upon contract manufacturing organizations and raw material suppliers making it vulnerable to supply shortages and problems, increased costs and quality or compliance issues.
• The company may not be able to generate sufficient cash to service all of its indebtedness and may be forced to take other actions to satisfy its obligations under its indebtedness, which may not be successful.
• The company is highly dependent on key members of its executive management team.
• Exchange rate fluctuations between the U.S. dollar and the New Israeli Shekel and inflation may negatively affect the company's results of operations.
• Political, economic and military instability in the State of Israel may adversely affect the company's results of operations.

Future Outlook

The company anticipates continuing to incur significant losses for the foreseeable future as operating expenses and capital expenditures increase. They believe that the existing cash, cash equivalents and short-term deposits, will be sufficient to enable them to fund their operating expenses and capital expenditure requirements through June 30, 2025. They anticipate that these funds, together with the net proceeds of this offering, will be sufficient to fund their operating expenses and capital expenditure requirements through March 31, 2027, including the completion of their pivotal trial for GelrinC with the two-year follow-up required by the FDA.

Industry Context

The announcement comes amid growing interest in regenerative medicine and orthopedic treatments, particularly for cartilage repair. The company is positioning itself to compete with existing surgical and cell-based therapies by offering a cost-effective, off-the-shelf solution.

Comparison to Industry Standards

• The document mentions Vericel's MACI as a competing therapy, noting its higher cost (~$40,000) and more complex two-surgery procedure compared to GelrinC's single-surgery approach.
• The document also references microfracture surgery as the current standard of care, highlighting GelrinC's potential for longer-term positive outcomes compared to the shorter-term relief provided by microfracture.
• The document mentions CartiHeals (acquired by Smith & Nephew in January 2024) Agili-C, which was approved by the FDA in March 2022, that utilizes pre-formed implants that consist of a two layer plug, of which the lower layer is a mineral/coral material that has been shaped to be inserted into a hole drilled into bone, which part is expected to assimilate with the bone, and the upper layer part is a scaffold intended to serve as a growth host for the cartilage cells.

Legal Proceedings

• The company is involved in a payment dispute with CSL Behring GmbH regarding unshipped minimum purchase commitments, with ongoing legal proceedings in Germany and Israel.

Related Party Transactions

• The company has entered into bridge loan agreements with certain lenders, including Dr. Ehud Geller, the chairman and a member of the board of directors, and Pini Ben Elazar, a director nominee.
• The company has entered into loan agreements with certain lenders, including Dr. Ehud Geller, the chairman and a member of the board of directors and SCP Vitalife Partners (which is affiliated with our director, Jeff Dykan).
• The company entered into a loan agreement with our Chief Executive Officer, according to which accrued payroll salary owed to him was converted into a loan.
• The company rents its office in Herzliya, Israel from E.G Archimedes Ltd, which is under the Companys executive chairmans control.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises and volatility in the market price of Ordinary Shares.
• Employees: Job security dependent on the company's ability to secure funding and achieve commercial success.
• Patients: Potential access to a new and innovative treatment for cartilage repair.
• Customers (Healthcare Professionals): Opportunity to offer a cost-effective and simple-to-use solution for cartilage injuries.

Next Steps

• Complete patient enrollment and required follow-up of the GelrinC pivotal trial.
• Apply for PMA marketing approval upon successful completion of the pivotal trial.
• Seek strategic partners for marketing GelrinC in the United States and Europe.
• Develop a pipeline of products for additional tissue regeneration opportunities.

Key Dates

Keywords

GelrinC, Regenerative medicine, Cartilage repair, IPO, Biomaterials, Orthopedic, FDA, Clinical trial, Hydrogel, PMA